Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies
Colorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant for patient stratification in molecularly-guided clinical trials. The consensus molecular subtypes (CMSs) and colorectal cancer intrinsic subtypes (CRISs) transcriptional signatures have potential clinical utility fo...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
Wiley
2018
|
| _version_ | 1826257245051027456 |
|---|---|
| author | Alderdice, M Richman, S Gollins, S Stewart, J Hurt, C Adams, R McCorry, A Roddy, A Vimalachandran, D Isella, C Medico, E Maughan, T McArt, D Lawler, M Dunne, P |
| author_facet | Alderdice, M Richman, S Gollins, S Stewart, J Hurt, C Adams, R McCorry, A Roddy, A Vimalachandran, D Isella, C Medico, E Maughan, T McArt, D Lawler, M Dunne, P |
| author_sort | Alderdice, M |
| collection | OXFORD |
| description | Colorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant for patient stratification in molecularly-guided clinical trials. The consensus molecular subtypes (CMSs) and colorectal cancer intrinsic subtypes (CRISs) transcriptional signatures have potential clinical utility for improving prognostic/predictive patient assignment. However, their ability to provide robust classification, particularly in pretreatment biopsies from multiple regions or at different time points, remains untested. In this study, we undertook a comprehensive assessment of the robustness of CRC transcriptional signatures, including CRIS and CMS, using a range of tumour sampling methodologies currently employed in clinical and translational research. These include analyses using (i) laser-capture microdissected CRC tissue, (ii) eight publically available rectal cancer biopsy data sets (n = 543), (iii) serial biopsies (from AXEBeam trial, NCT00828672; n = 10), (iv) multi-regional biopsies from colon tumours (n = 29 biopsies, n = 7 tumours), and (v) pretreatment biopsies from the phase II rectal cancer trial COPERNCIUS (NCT01263171; n = 44). Compared to previous results obtained using CRC resection material, we demonstrate that CMS classification in biopsy tissue is significantly less capable of reliably classifying patient subtype (43% unknown in biopsy versus 13% unknown in resections, p = 0.0001). In contrast, there was no significant difference in classification rate between biopsies and resections when using the CRIS classifier. Additionally, we demonstrated that CRIS provides significantly better spatially- and temporally- robust classification of molecular subtypes in CRC primary tumour tissue compared to CMS (p = 0.003 and p = 0.02, respectively). These findings have potential to inform ongoing biopsy-based patient stratification in CRC, enabling robust and stable assignment of patients into clinically-informative arms of prospective multi-arm, multi-stage clinical trials. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. |
| first_indexed | 2024-03-06T18:15:05Z |
| format | Journal article |
| id | oxford-uuid:04585253-91b5-4bf0-bd6e-dcc193304ea2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:15:05Z |
| publishDate | 2018 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:04585253-91b5-4bf0-bd6e-dcc193304ea22022-03-26T08:51:19ZProspective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsiesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:04585253-91b5-4bf0-bd6e-dcc193304ea2EnglishSymplectic Elements at OxfordWiley2018Alderdice, MRichman, SGollins, SStewart, JHurt, CAdams, RMcCorry, ARoddy, AVimalachandran, DIsella, CMedico, EMaughan, TMcArt, DLawler, MDunne, PColorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant for patient stratification in molecularly-guided clinical trials. The consensus molecular subtypes (CMSs) and colorectal cancer intrinsic subtypes (CRISs) transcriptional signatures have potential clinical utility for improving prognostic/predictive patient assignment. However, their ability to provide robust classification, particularly in pretreatment biopsies from multiple regions or at different time points, remains untested. In this study, we undertook a comprehensive assessment of the robustness of CRC transcriptional signatures, including CRIS and CMS, using a range of tumour sampling methodologies currently employed in clinical and translational research. These include analyses using (i) laser-capture microdissected CRC tissue, (ii) eight publically available rectal cancer biopsy data sets (n = 543), (iii) serial biopsies (from AXEBeam trial, NCT00828672; n = 10), (iv) multi-regional biopsies from colon tumours (n = 29 biopsies, n = 7 tumours), and (v) pretreatment biopsies from the phase II rectal cancer trial COPERNCIUS (NCT01263171; n = 44). Compared to previous results obtained using CRC resection material, we demonstrate that CMS classification in biopsy tissue is significantly less capable of reliably classifying patient subtype (43% unknown in biopsy versus 13% unknown in resections, p = 0.0001). In contrast, there was no significant difference in classification rate between biopsies and resections when using the CRIS classifier. Additionally, we demonstrated that CRIS provides significantly better spatially- and temporally- robust classification of molecular subtypes in CRC primary tumour tissue compared to CMS (p = 0.003 and p = 0.02, respectively). These findings have potential to inform ongoing biopsy-based patient stratification in CRC, enabling robust and stable assignment of patients into clinically-informative arms of prospective multi-arm, multi-stage clinical trials. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. |
| spellingShingle | Alderdice, M Richman, S Gollins, S Stewart, J Hurt, C Adams, R McCorry, A Roddy, A Vimalachandran, D Isella, C Medico, E Maughan, T McArt, D Lawler, M Dunne, P Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies |
| title | Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies |
| title_full | Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies |
| title_fullStr | Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies |
| title_full_unstemmed | Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies |
| title_short | Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies |
| title_sort | prospective patient stratification into robust cancer cell intrinsic subtypes from colorectal cancer biopsies |
| work_keys_str_mv | AT alderdicem prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT richmans prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT gollinss prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT stewartj prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT hurtc prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT adamsr prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT mccorrya prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT roddya prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT vimalachandrand prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT isellac prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT medicoe prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT maughant prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT mcartd prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT lawlerm prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies AT dunnep prospectivepatientstratificationintorobustcancercellintrinsicsubtypesfromcolorectalcancerbiopsies |